Navigation Links
Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference
Date:5/16/2008

SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Citi Investment Research Global Healthcare Conference in New York City on May 22, 2008 at 9:30 a.m. EDT.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Anesiva to Unveil Zingo(TM) Commercialization Plans
2. Anesiva to Present at BIO InvestorForum on October 11, 2007
3. Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007
4. Anesiva Announces Upcoming Webcasts and Conference Participation
5. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
6. Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... of unique liquid food supplements, announced its popular products are now available for ... , ALP Nutrition® prioritizes the use of premium natural ingredients in making all ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus ... announces the company’s VideoMedicine mobile platform has launched Quick Care, a new service ... day, Quick Care provides patients with the option to request and begin a ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, ... HIV because it is not known to have significant interactions with antiretroviral therapy ... both lower cholesterol levels and dampen inflammation in the bloodstream. , While lowering ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology: